CDMO Services

Pioneering Patented Plant-Based Molecules at Industrial Scale

BioHarvest’s breakthrough Botanical Synthesis technology enables partnering companies to own patented plant-based small and complex molecules for the first time in history. Our B2B CDMO Division can now develop unique, protected compounds with unprecedented purity and consistency – creating powerful barriers to entry for partner products.

Our CDMO platform transforms traditional botanical production into a precise science. By optimizing plant cells in controlled environments, BioHarvest creates novel, patentable compounds that were previously impossible to produce at commercial scale. This isn’t just manufacturing – it’s the future of botanical intellectual property.

Partners gain exclusive rights to unique molecules through BioHarvest’s phase by phase development process and licensing model, enabling true product differentiation backed by patent protection. We provide a clear pathway from initial concept through commercial production, allowing partners to create their own proprietary botanical compounds.

BioHarvest Sciences Botanical Synthesis CDMO has the Potential to Become an Emerging Force in Plant-based Biologics

Tate & Lyle Expands Collaboration with BioHarvest to Accelerate Next-Generation Sweetener Innovation

Expanded sweetener molecule development program aims to broaden access to plant‑based sweetening solutions tailored to diverse customer food and beverage categories.

London, UK and Vancouver, Canada – May 18^th, 2026 – BioHarvest Sciences Inc. (Nasdaq: BHST), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their joint sweetener development program to include multiple plant‑based sweetener molecules.

The expanded collaboration builds on the initial agreement signed in 2024 and reflects strong technical progress to date, as well as Tate & Lyle’s ambition to equip food and beverage manufacturers with a flexible toolkit of sweetening solutions that can be tailored to different formulation needs.

The Biologics+ CDMO Services Offering

Expansion into the contract development & manufacturing organization (CDMO) market is built upon the success of our commercially validated botanical synthesis technology process
The CDMO Services division enables BioHarvest to offer disruptive innovation via Botanical Synthesis for market leaders in cosmeceutical, nutraceutical & food nutrition verticals with unique plant molecules and compounds
Development of plant-based Biologics+ compounds creates a safer, faster and less expensive pipeline of molecules for next-generation therapeutics vs existing small and complex molecule solutions available to pharma.
CDMO partners own all IP rights to the new developed compounds
Biologics+ can be pursued through full FDA-approved drugs in both regulatory approval pathways: Biological drugs and Botanical drugs
CDMO unit provides BioHarvest a unique optionality on top of existing high performing products business

Staged Gate Development Approach to Ensure Success

Development Timeline: 18-27 Months

Non-Recurring Engineering (NRE) Costs: $2.5M – $3.0M, paid for by CDMO partner

Discovery Stage is now available for partners seeking to match plant compound candidates with their targeted indications
Stage 1 begins with customer initiation where specific plant and compounds are chosen; cell culture development and elicitation completed
Within 6-9 months customer can receive kilograms of molecules for development and clinical trials
Development completes with industrial production of chosen compound and royalty model put into place with customer (expected to be ~80% gross margins)